Liver Cancer Incidence is on the Rise in the United States (05/25/2010)
From 2001 to 2006, the incidence of hepatocellular carcinoma (HCC) increased significantly with an average increase of 3.5% annually. This analysis was recently reported in the Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report.

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (05/17/2010)
According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than treatment with Gemzar alone.

Liver Cancer Often Linked to Diabetes (05/04/2010)
Diabetes increases the risk of hepatocellular carcinoma (HCC) and may account for a greater number of HCC cases in the United States than any other single HCC risk factor. These results were presented at the 101^st annual meeting of the American Association for Cancer Research.

Sutent® Not Effective for Advanced Liver Cancer (07/10/2009)
In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology.

Women with Hypothyroidism at Increased Risk of Liver Cancer (06/22/2009)
Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.

▪ More...

Sutent® Not Effective for Advanced Liver Cancer (07/10/2009)
In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology.

Women with Hypothyroidism at Increased Risk of Liver Cancer (06/22/2009)
Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.

Risk of Needle Track Seeding Following Biopsy for HCC is 2.7% (10/30/2008)
The risk of the spread of cancer along the path of the needle (needle track seeding) during a biopsy for hepatocellular carcinoma (HCC) is approximately 2.7%. These results were recently published in the journal Gut.

Genes Outside of Cancer Help Predict Outcomes of Liver Cancer Patients (10/21/2008)
Genes that can be measured directly adjacent to the site of a liver cancer can help predict survival among patients diagnosed with the most common type of liver cancer, hepatocellular carcinoma. These results were recently published in the New England Journal of Medicine.

Genetic Characteristics of Hepatitis B Associated with Risk of Liver Cancer (08/29/2008)
Different genetic characteristics of the hepatitis B virus (HBV) are associated with varying risks of developing hepatocellular carcinoma (HCC), the most common form of liver cancer. These results were recently published in the Journal of the National Cancer Institute.

▪ More...

Arterial Embolization Effective in Patients with Liver Cancer Recurrence (06/26/2006)
In selected patients who have a cancer recurrence following surgical removal of liver cancer, arterial embolization (blocking the arteries that supply blood to a tumor) appears to produce good survival results. These results were published in the journal Cancer.

Repeat Surgery for Recurrent Liver Cancer Provides Long-Term Survival in Subset of Patients (10/30/2003)
According to results recently published in the Annals of Surgery, repeat surgery for recurrent liver cancer provides long-term survival in a subset of patients.

Radiofrequency Ablation Reduces Local Recurrences Compared to Cryosurgery for Treatment of Inoperable Liver Cancer or Metastasis to the Liver (01/09/2003)
According to a recent article published in the Archives of Surgery, radiofrequency ablation appears to be superior to cryosurgery for the treatment of inoperable liver cancer or metastasis to the liver.

Doxil® Produces Anti-Cancer Responses in Advanced Cancers of the Liver and Bile Duct (10/14/2002)
According to results presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Doxil® produces anti-cancer responses in patients with advanced cancers of the liver (hepatocellular) and bile duct (cholangiocarcinoma).

Radiation Therapy, Combined with Chemoembolization, Appears Effective in Some Persons with Inoperable Liver Cancer (02/14/2002)
The use of radiation therapy can be effective in prolonging the survival time for some persons with inoperable liver cancer, according to a recent report from researchers in Taiwan. These investigators also noted that the combination of radiation therapy and chemoembolization may offer an added benefit in the treatment of some persons with this disease.

▪ More...

Liver Cancer Incidence is on the Rise in the United States (05/25/2010)
From 2001 to 2006, the incidence of hepatocellular carcinoma (HCC) increased significantly with an average increase of 3.5% annually. This analysis was recently reported in the Centers for Disease Control and Prevention’s (CDC) Morbidity and Mortality Weekly Report.

Liver Cancer Often Linked to Diabetes (05/04/2010)
Diabetes increases the risk of hepatocellular carcinoma (HCC) and may account for a greater number of HCC cases in the United States than any other single HCC risk factor. These results were presented at the 101^st annual meeting of the American Association for Cancer Research.

Women with Hypothyroidism at Increased Risk of Liver Cancer (06/22/2009)
Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.

Incidence of Liver Cancer on the Rise (04/08/2009)
The incidence of liver cancer in the United States tripled between 1975 and 2005, but survival rates are improving, according to the results of a study published in the Journal of Clinical Oncology.

Moderate Alcohol Consumption Increases Risk of Cancer in Women (03/10/2009)
Women who regularly consume low to moderate amounts of alcohol have an increased risk of cancers of the upper digestive tract, rectum, liver, and breast when compared with women who do not drink, according to the results of a study published in the Journal of the National Cancer Institute.

▪ More...

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (05/17/2010)
According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than treatment with Gemzar alone.

Sutent® Not Effective for Advanced Liver Cancer (07/10/2009)
In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology.

Combination of Chemotherapy Drugs Improves Survival with Biliary Tract Cancer (05/20/2009)
According to the results of a Phase III clinical trial that will be presented at the 2009 annual meeting of the American Society of Clinical Oncology (ASCO), treatment of gallbladder or bile duct cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than treatment with Gemzar alone.

Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma (02/03/2009)
According to the results of a Phase II clinical trial, the combination of two targeted therapies—Avastin® (bevacizumab) and Tarceva® (erlotinib)—has anticancer activity in patients with advanced hepatocellular (liver) cancer and warrants further study. These results were published in the Journal of Clinical Oncology.

Nexavar® Effective for Hepatocellular Carcinoma in Asians (01/21/2009)
Researchers from 23 medical centers in Asia have reported that Nexavar® (sorafenib) is effective in patients with advanced hepatocellular carcinoma (liver cancer). The results of this study were published in Lancet Oncology.

▪ More...

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (05/17/2010)
According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than treatment with Gemzar alone.

Sutent® Not Effective for Advanced Liver Cancer (07/10/2009)
In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology.

Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma (02/03/2009)
According to the results of a Phase II clinical trial, the combination of two targeted therapies—Avastin® (bevacizumab) and Tarceva® (erlotinib)—has anticancer activity in patients with advanced hepatocellular (liver) cancer and warrants further study. These results were published in the Journal of Clinical Oncology.

Nexavar® Effective for Hepatocellular Carcinoma in Asians (01/21/2009)
Researchers from 23 medical centers in Asia have reported that Nexavar® (sorafenib) is effective in patients with advanced hepatocellular carcinoma (liver cancer). The results of this study were published in Lancet Oncology.

Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer (04/04/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in liver cancer difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.

▪ More...